Pfizer Settles Large Group of HRT Cases

Printer-friendly version
Tom Bassinger, MCM News

Pfizer, the world’s largest drug maker, has reportedly agreed to settle one-third of the approximately 10,000 pending cases in which plaintiffs’ have alleged that Pfizer failed to properly warn of the risk of taking Prempro, a hormone replacement therapy (HRT) drug that was prescribed to women to treat symptoms of menopause.

Pfizer stated that it set aside $772 million to resolve these cases and noted that this reserve provided “the minimum expected costs to resolve all of the other outstanding” lawsuits over its  HRT drugs.  Pfizer has refused to comment on average settlement amounts but reportedly settled 2200 cases in February for about $330 million representing an average settlement of about $150,000.

An extensive 2002 study revealed that HRT therapy was found to pose serious health risks such as stroke, heart attack and breast cancer. Over six million women took Prempro and related menopause drugs to treat symptoms such as hot flashes and mood swings before this study highlighted their links to cancer.

Click here to read more on this story.


BHI Online houses an archive of hormone-related citations for biomedical literature. Also provided are links to PubMed and the NCBI molecular biology resources.


BHI Online strives to support healthcare professionals through webinars presented by leading experts in their respective fields.


Join the conversation with BHI Online's forums aimed at providing information through communities.

Latest News

A selection of stories and articles making headlines in the field of Bioidentical Hormone therapies.

Get In Touch

Locate a BHRT doctor, submit an article or just say hello, we'd love to meet you.

Sub Page: Side Block 1

Sub Page: Side Block 2

Sub Page: Side Block 3

Sub Page: Side Block 4